Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Is Supporting Development Across The Remicade Biosimilar Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Remicade Biosimilar Market By 2030 Based On Its 2026 Value?

The remicade biosimilar market has seen substantial growth in recent years. Its valuation is set to increase from $4.89 billion in 2025 to $5.97 billion in 2026, reflecting a compound annual growth rate (CAGR) of 22.2%. This historical expansion can be attributed to several factors, including the significant financial burden of branded biologics, the expiration of remicade’s patent, a growing incidence of autoimmune diseases, governmental initiatives supporting biosimilar approvals, and purchasing models such as hospital-driven bulk procurement.

The remicade biosimilar market is projected to experience substantial expansion over the coming years, reaching $13.31 billion in 2030 with a compound annual growth rate (CAGR) of 22.2%. This expansion during the forecast period is propelled by factors such as the increasing need for economical biologic treatments, the broadening of biosimilar development pipelines, escalating healthcare spending in developing nations, greater acceptance among medical professionals and patients, and supportive reimbursement structures. Key developments anticipated during this timeframe involve a greater uptake of budget-friendly biosimilars, strengthening confidence among prescribers in infliximab biosimilars, the broadening of their approved uses for autoimmune conditions, a focus on competitive pricing and tender-based purchasing methods, and deeper market penetration in nascent healthcare markets.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

Which Strategic Drivers Are Supporting The Remicade Biosimilar Market Development?

The increasing occurrence of autoimmune diseases is anticipated to boost the expansion of the remicade biosimilar market. These conditions involve the immune system erroneously attacking the body’s own tissues and organs. Remicade biosimilars offer a valuable treatment approach for autoimmune diseases, helping to manage symptoms and decrease inflammation. For example, data released in February 2024 by Arthritis Australia, a charitable non-profit based in Australia, indicates that by 2025, around 562,378 Australians are predicted to suffer from rheumatoid arthritis (RA), making up 14% of the entire arthritis population. This figure is forecasted to increase by 33% to roughly 748,721 individuals by 2040. Consequently, the growing prevalence of autoimmune diseases is fueling the growth of the remicade biosimilar market.

How Are Different Segment Groups Identified Within The Remicade Biosimilar Market?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Which Trends Are Influencing The Direction Of The Remicade Biosimilar Market?

Leading companies in the remicade biosimilar market are concentrating on creating innovative solutions, such as subcutaneous formulations, to achieve a competitive edge. Subcutaneous formulations of Remicade present an alternative method of administration for treating autoimmune diseases, allowing for patient self-administration and potentially improving adherence to therapy. For instance, in March 2024, Celltrion, a South Korea-based biopharmaceutical company, introduced Zymfentra, a biosimilar to Remicade (infliximab), at $6,181.08 for two doses over four weeks. This product received FDA approval as the first subcutaneous infliximab formulation for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn’s disease. Commercially insured patients who are eligible can receive copay assistance of $5 per month, and patients who are uninsured or underinsured may obtain Zymfentra at no cost.

Which Companies Are Engaged In The Remicade Biosimilar Market Environment?

Major companies operating in the remicade biosimilar market are Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., BioXpress Therapeutics SA, Mabion S.A

Access The Complete Remicade Biosimilar Market Report:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Region Holds The Largest Share In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2025. The regions covered in the remicade biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Remicade Biosimilar Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

Browse Through More Reports Similar to the Global Remicade Biosimilar Market 2026, By The Business Research Company

Remicade Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Biotechnology Reagents Market Report 2026

https://www.thebusinessresearchcompany.com/report/biotechnology-reagents-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795